Literature DB >> 12702589

Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis.

Yukihiko Sonoda1, Masayuki Kanamori, Dennis F Deen, Shi-Yuan Cheng, Mitchel S Berger, Russell O Pieper.   

Abstract

Vascular endothelial growth factor (VEGF) is thought to promote tumor growth and angiogenesis. Whereas VEGF is up-regulated in only a portion of anaplastic astrocytoma (AA), it is overexpressed in most glioblastoma multiforme (GBM), and the level of expression is correlated with grade of glioma. To explore the possibility that VEGF may act as a driving force in the progression of AA to GBM, the VEGF isoforms VEGF(121) and VEGF(165) were overexpressed in genetically modified, mutant H-Ras-transformed human astrocytes that on intracranial implantation form AA-like tumors. The ability of the VEGF isoforms to stimulate growth, angiogenesis, oxygenation, and the formation of necrotic GBM-like tumors was then monitored. The parental mutant H-Ras-modified astrocytes expressed four times more endogenous VEGF than normal human astrocytes, but on intracranial implantation formed hypovascular, hypoxic, small AA-like tumors. Whereas these modest levels of VEGF overexpression were insufficient to drive oxygenation and GBM formation, an additional 8-fold increase in VEGF expression mediated by retroviral infection with constructs encoding either VEGF (121) or VEGF (165) resulted in cells which, after intracranial implantation, formed tumors that were larger, more vascular, and better oxygenated than those formed by the mutant H-ras parental cells. However, the tumors formed by the cells expressing exogenous VEGF (121) or VEGF (165) retained the phenotype of AA, lacking areas of necrosis that are the hallmark of the GBM phenotype. These results suggest that whereas the VEGF(121) and VEGF(165) isoforms can contribute to glioma vascularization, oxygenation, and growth, they do not in and of themselves drive the formation of the GBM phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702589

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers.

Authors:  Anjali Shiras; Arti Bhosale; Varsha Shepal; Ravi Shukla; V S Baburao; K Prabhakara; Padma Shastry
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

2.  Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.

Authors:  Sun-Jin Kim; Ho Jeong Lee; Mark Seungwook Kim; Hyun Jin Choi; Junqin He; Qiuyu Wu; Kenneth Aldape; Jeffrey S Weinberg; W K Alfred Yung; Charles A Conrad; Robert R Langley; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2015-06-23       Impact factor: 12.531

3.  Inhibition of Nodal suppresses angiogenesis and growth of human gliomas.

Authors:  Dueng-Yuan Hueng; Gu-Jiun Lin; Shing-Hwa Huang; Li-Wen Liu; Da-Tong Ju; Yuan-Wu Chen; Huey-Kang Sytwu; Chen Chang; Shih-Ming Huang; Yi-Shian Yeh; Horng-Mo Lee; Hsin-I Ma
Journal:  J Neurooncol       Date:  2010-11-30       Impact factor: 4.130

4.  Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.

Authors:  Shigeo Ohba; Joydeep Mukherjee; Tor-Christian Johannessen; Andrew Mancini; Tracy T Chow; Matthew Wood; Lindsey Jones; Tali Mazor; Roxanne E Marshall; Pavithra Viswanath; Kyle M Walsh; Arie Perry; Robert J A Bell; Joanna J Phillips; Joseph F Costello; Sabrina M Ronen; Russell O Pieper
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

Review 5.  Brain endothelial cells as pharmacological targets in brain tumors.

Authors:  Michel Demeule; Anthony Régina; Borhane Annabi; Yanick Bertrand; Michel W Bojanowski; Richard Béliveau
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

6.  Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.

Authors:  Oszkar Szentirmai; Cheryl H Baker; Szofia S Bullain; Ning Lin; Masaya Takahashi; Judah Folkman; Richard C Mulligan; Bob S Carter
Journal:  J Neurosurg       Date:  2008-05       Impact factor: 5.115

7.  A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis.

Authors:  J H Tchaicha; A K Mobley; M G Hossain; K D Aldape; J H McCarty
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 8.  Research progress of anti-glioma chemotherapeutic drugs (Review).

Authors:  Yi-Shu Zhou; Wei Wang; Na Chen; Li-Cui Wang; Jin-Bai Huang
Journal:  Oncol Rep       Date:  2022-04-01       Impact factor: 3.906

Review 9.  Neurovascular patterning cues and implications for central and peripheral neurological disease.

Authors:  Nicholas T Gamboa; Philipp Taussky; Min S Park; William T Couldwell; Mark A Mahan; M Yashar S Kalani
Journal:  Surg Neurol Int       Date:  2017-09-06

10.  Evaluation of VEGF, FGF and PDGF and Serum Levels of Inflammatory Cytokines in Patients with Glioma and Meningioma in Southern Iran.

Authors:  Seyedeh Azra Shamsdin; Ali Mehrafshan; Seyed Mohammad Rakei; Davood Mehrabani
Journal:  Asian Pac J Cancer Prev       Date:  2019-10-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.